Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGH | Q92820 | 2/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.45 |
| ▸ | CPA3 | P15088 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368136 | 0.85 | GGH (0.52) | GGHNAALAD2FOLH1MME | |
| SCHEMBL1374225 | 0.82 | GGH (0.65) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL1374224 | 0.82 | GGH (0.65) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL2368768 | 0.79 | GGH (0.54) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL7642260 | 0.78 | GGH (0.57) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL2368758 | 0.78 | GGH (0.59) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL2368764 | 0.78 | GGH (0.59) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL2368107 | 0.78 | GGH (0.68) | GGHNAALAD2FOLH1GAAMMP9 | |
| SCHEMBL7644441 | 0.77 | GGH (0.56) | GGHNAALAD2FOLH1CPA3GAA | |
| SCHEMBL2368267 | 0.77 | GGH (0.58) | GGHNAALAD2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091693-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2024-09-17 | — | — | US | disclosed |
| US-20220098564-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2022-03-31 | — | — | US | disclosed |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2020-09-10 | — | — | US | disclosed |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011106639-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098564-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
| US-12091693-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | GGH 205/4885NAALAD2 47/4885FOLH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.